Archives for


Possible Chemotherapy Replacement From Dana-Farber Cancer Institute in Boston

 Newly reported data for AstraZeneca Plc (AZN)’s experimental cancer treatments “gives credibility” to the drugmaker’s forecast of $45 billion in annual revenue by 2023, according to Chief Executive Officer Pascal Soriot. The release of information on AstraZeneca’s new medicines this weekend at the American Society of Clinical Oncology meeting should lessen skepticism about the prediction,

Pfizer Ends AstraZeneca Deal Over Chinese Food, Sniping

 Even in a high-stakes deal worth almost $120 billion, one that would create the world’s biggest drugmaker, the personal details matter. In a postmortem of the failed takeover talks between Pfizer Inc. (PFE) and AstraZeneca Plc (AZN), a surprise offer, disagreement over a press release and the difference between a personal visit and a telephone

Pfizer Raises AstraZeneca Offer to $106.5 Billion

 Pfizer Inc. (PFE) sweetened its bid for AstraZeneca Plc (AZN) to about 63.1 billion pounds ($106.5 billion), aiming to bring the U.K.’s second-biggest drugmaker to the negotiating table. The offer values AstraZeneca at 50 pounds a share in cash and stock, New York-based Pfizer said in statement today. The London-based company rejected a proposal of

Big Pharma: Pfizer Planning to Raise AstraZeneca Bid Above $106 Billion

Pfizer Inc. (PFE) is preparing to sweeten its bid for AstraZeneca Plc (AZN) to more than 63 billion pounds ($106 billion) in an attempt to lure the U.K.’s second-biggest drugmaker to the negotiating table, people with knowledge of the matter said. The offer may value AstraZeneca at more than 50 pounds a share and include